<span style="margin-left: 0em;">immune chekpoint inhibitors</span> <span style="margin-left: 1em;">anti-PD-(L)1</span> <span style="margin-left: 2em;">nivolumab based treatment</span> <span style="margin-left: 3em;">nivolumab alone <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 1em;">Immune checkpoint association</span> <span style="margin-left: 2em;">nivolumab plus ipilimumab <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span> <span style="margin-left: 0em;">non active control</span> <span style="margin-left: 1em;">placebo <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
deaths (OS) (2) progression or deaths (PFS) (2) objective responses (ORR) (2) DOR (2) TRAE (any grade) (2) TRAE (grade 3-4) (2) TRAE leading to death (grade 5) (2) TRAE leading to discontinuation (any grade) (2)
Network meta-analysis for deaths_(OS)
Network meta-analysis estimations pool direct and indirect evidences. These results should be considered as exploratory given the absence
of assessment of transitivity assumption plausibility. Calculations by netmeta package.
Evidence network for deaths_(OS)
1 CheckMate 451 (NI ; all population), 2019 1 CheckMate 451 (N ; all population), 2019 nivolumab alone vs. nivolumab plus ipilimumab
0.91 [0.69; 1.21] 0.91 [0.69;1.21]nivolumab alone vs. nivolumab plus ipilimumab
0.91 [0.69; 1.21] nivolumab alone vs. placebo
0.84 [0.69; 1.02] 0.84 [0.69;1.02]nivolumab alone vs. placebo
0.84 [0.69; 1.02] nivolumab plus ipilimumab vs. nivolumab alone
1.10 [0.83; 1.45] 1.10 [0.83;1.45]nivolumab plus ipilimumab vs. nivolumab alone
1.10 [0.83; 1.45] nivolumab plus ipilimumab vs. placebo
0.92 [0.75; 1.12] 0.92 [0.75;1.12]nivolumab plus ipilimumab vs. placebo
0.92 [0.75; 1.12] placebo vs. nivolumab alone
1.19 [0.98; 1.45] 1.19 [0.98;1.45]placebo vs. nivolumab alone
1.19 [0.98; 1.45] placebo vs. nivolumab plus ipilimumab
1.09 [0.89; 1.33] 1.09 [0.89;1.33]placebo vs. nivolumab plus ipilimumab
1.09 [0.89; 1.33] placebo nivolumab plus ipilimumab nivolumab alone direct evidence network meta-analysis comet plot result box odds ratio A B 0.5 1.5 1.0 odds ratio for A vs. B and half 95% CI
T vs. C placebo nivolumab plus ipilimumab nivolumab alone placebo --- 1.09 0.89; 1.331.19 0.98; 1.45nivolumab plus ipilimumab 0.92 0.75; 1.12--- 1.10 0.83; 1.45nivolumab alone 0.84 0.69; 1.020.91 0.69; 1.21---
pathologies: 194
- treatments: 360,719,721,720
result logic